dx 8951 has been researched along with Experimental Mammary Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, Y; Ashida, S; Honda, T; Kasuya, Y; Masuda, T; Miyazaki, H; Morita, K; Naito, H; Nakada, T; Ogitani, Y; Yamaguchi, J; Yoshida, M | 1 |
1 other study(ies) available for dx 8951 and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Injections, Intraventricular; Mammary Neoplasms, Experimental; Mice; Molecular Conformation; Structure-Activity Relationship; Trastuzumab | 2016 |